نتائج البحث - "Masafumi Sata"

1

Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer

المؤلفون: Koichi Hagiwara, Kazutaka Fujita, Masafumi Sata, Nobuyuki Hizawa, Masayuki Nakayama, Naoko Mato, Takuji Suzuki, Yoshiaki Nagai, Shu Hisata, Masashi Bando

المصدر: Cancer Medicine
Cancer Medicine, Vol 10, Iss 23, Pp 8595-8603 (2021)

مصطلحات موضوعية: Peptide Nucleic Acids, Proto-Oncogene Proteins B-raf, Cancer Research, Lung Neoplasms, DNA polymerase, medicine.disease_cause, Polymerase Chain Reaction, Sensitivity and Specificity, secondary mutation, Proto-Oncogene Proteins p21(ras), chemistry.chemical_compound, Bronchoscopy, cytological samples, medicine, Humans, Radiology, Nuclear Medicine and imaging, Locked nucleic acid, Lung cancer, cell‐free DNA, RC254-282, Research Articles, Neoplasm Staging, Cancer Biology, biology, Peptide nucleic acid, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Sequence Analysis, DNA, medicine.disease, Molecular biology, ErbB Receptors, lung cancer, Oncology, chemistry, Cell-free fetal DNA, Mutation, biology.protein, Nucleic acid, KRAS, EGFR mutation, Cell-Free Nucleic Acids, Nucleic Acid Amplification Techniques, DNA, Research Article

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bac55aea11df3ea4e242a122a90c18dTest
https://doi.org/10.1002/cam4.4330Test

2

Herpes zoster in patients with lung cancer treated with PD-1/PD-L1 antibodies

المؤلفون: Yoshiaki Nagai, Masafumi Sata, Hiromitsu Ohta, Tsugitoshi Onuki, Tatsuya Saito, Ayumi Uchiyama, Ayako Kurosaki, Naoko Yoshizumi, Ayako Takigami, Shoko Nakazawa, Masayuki Nakayama, Hironori Yamaguchi, Koichi Hagiwara

المصدر: Immunotherapy. 14(15)

مصطلحات موضوعية: ErbB Receptors, Lung Neoplasms, Oncology, Carcinoma, Non-Small-Cell Lung, Immunology, Programmed Cell Death 1 Receptor, Immunology and Allergy, Humans, Herpes Zoster, Protein Kinase Inhibitors, B7-H1 Antigen, Retrospective Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef8835d963d179179584212b2ff4a80bTest
https://pubmed.ncbi.nlm.nih.gov/36039980Test

3

Inhibitory effects of somatostatin analogue in bleomycin-induced pulmonary fibrosis

المؤلفون: Masafumi Sata, Masashi Bando, Tatsuya Hosono, Yoshiko Mizushina, Yukihiko Sugiyama, Koichi Hagiwara

المصدر: Experimental Lung Research. 47:280-288

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da439327169bde944427f1259cdad9c1Test
https://doi.org/10.1080/01902148.2021.1916650Test

4

Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non–small cell lung cancer

المؤلفون: Yoshinobu Saito, Masafumi Sata, Yoshihiko Ito, Takahiko Sakamoto, Yuichiro Ohe, Noriyo Yanagawa, Masahiko Kusumoto, Shinichi Sasaki, Tomohisa Baba, Tae Iwasawa, Kazuyoshi Kuwano, Hiroaki Sugiura, Yutaka Fujiwara, Masahiro Endo, Terufumi Kato, Junya Tominaga, Fumikazu Sakai, Katsunori Oikado, Hirotsugu Kenmotsu

المصدر: Cancer Science

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Pleural effusion, non‐small‐cell lung carcinoma, Gastroenterology, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Japan, Clinical Research, Risk Factors, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Carcinoma, interstitial lung diseases, Humans, Diffuse alveolar damage, Lung cancer, Lung, Aged, Retrospective Studies, nivolumab, computed X‐ray tomography, business.industry, Hazard ratio, Interstitial lung disease, prognostic factors, General Medicine, Middle Aged, respiratory system, Prognosis, medicine.disease, respiratory tract diseases, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Original Article, Female, ORIGINAL ARTICLES, Nivolumab, Lung Diseases, Interstitial, business, Cryptogenic Organizing Pneumonia

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c7e084a34fe1233978dafbf1da993ffTest
https://doi.org/10.1111/cas.14710Test

5

Treatment and relapse of interstitial lung disease in nivolumab‐treated patients with non–small cell lung cancer

المؤلفون: Yuichiro Ohe, Masafumi Sata, Kazuyoshi Kuwano, Yoshinobu Saito, Tomohisa Baba, Masahiko Kusumoto, Tae Iwasawa, Yoshihiko Ito, Takahiko Sakamoto, Yutaka Fujiwara, Terufumi Kato, Noriyo Yanagawa, Shinichi Sasaki, Junya Tominaga, Hirotsugu Kenmotsu, Masahiro Endo, Katsunori Oikado, Fumikazu Sakai, Hiroaki Sugiura

المصدر: Cancer Science

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, medicine.drug_class, medicine.medical_treatment, Interstitial lung disease, Adverse drug events, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, Japan, Clinical Research, Internal medicine, Carcinoma, Non-Small-Cell Lung, Carcinoma, Medicine, Humans, Lung cancer, Adverse effect, Aged, Retrospective Studies, business.industry, Antibodies, Monoclonal, Retrospective cohort study, General Medicine, Immunotherapy, respiratory system, Middle Aged, medicine.disease, Non‐small‐cell lung carcinoma, respiratory tract diseases, 030104 developmental biology, Nivolumab, Oncology, 030220 oncology & carcinogenesis, Corticosteroid, Original Article, Female, ORIGINAL ARTICLES, Neoplasm Recurrence, Local, business, Lung Diseases, Interstitial

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a45209a9c966db7d6ee4d6d12506a8dTest
http://europepmc.org/articles/PMC8019226Test

6

Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non–small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834)

المؤلفون: Satoshi Ikeda, Kentaro Tanaka, Masafumi Sata, Hiroshi Tanaka, Eiki Ichihara, Takeharu Yamanaka, Masaki Kanazu, Yuichi Takiguchi, Hiroaki Okamoto, Hidehito Horinouchi, Yasuhiro Goto, Koichi Hagiwara, Satoru Miura, Terufumi Kato

المصدر: Clinical Lung Cancer. 21:e592-e596

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Lung Neoplasms, medicine.medical_treatment, Afatinib, Carboplatin, chemistry.chemical_compound, T790M, 0302 clinical medicine, Japan, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Epidermal growth factor receptor, Aged, 80 and over, biology, Middle Aged, Prognosis, ErbB Receptors, Research Design, 030220 oncology & carcinogenesis, Female, medicine.drug, Adult, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Pemetrexed, Young Adult, 03 medical and health sciences, Internal medicine, medicine, Humans, Lung cancer, Aged, Chemotherapy, business.industry, medicine.disease, Clinical trial, 030104 developmental biology, chemistry, Mutation, biology.protein, Cisplatin, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00f9580e4e974a1d5123039d90f14b53Test
https://doi.org/10.1016/j.cllc.2020.05.011Test

7

Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan

المؤلفون: Yoshinobu Saito, Masahiko Kusumoto, Yuichiro Ohe, Masafumi Sata, Kei Sakamoto, Terufumi Kato, Toshimitsu Tokimoto, Reiko Tamura, Tomohisa Baba, Akihiko Gemma, Masatoshi Sugeno, Ou Yamaguchi, Wataru Shimizu, Masahiro Endo, Fumikazu Sakai

المصدر: Japanese Journal of Clinical Oncology

مصطلحات موضوعية: 0301 basic medicine, safety, Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Population, QT interval, Gastroenterology, Liver disorder, 03 medical and health sciences, 0302 clinical medicine, Japan, Internal medicine, Carcinoma, Non-Small-Cell Lung, Medicine, AcademicSubjects/MED00300, Humans, Radiology, Nuclear Medicine and imaging, Osimertinib, Lung cancer, education, Adverse effect, Protein Kinase Inhibitors, non-small cell lung cancer, Aged, education.field_of_study, Acrylamides, Aniline Compounds, business.industry, Interstitial lung disease, General Medicine, medicine.disease, Confidence interval, Progression-Free Survival, ErbB Receptors, Survival Rate, 030104 developmental biology, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, osimertinib, Mutation, Original Article, Female, business, epidermal growth factor receptor

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3b4556abdbca0ecb767d113e698aa22Test
http://europepmc.org/articles/PMC7401719Test

8

Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real‐world efficacy and safety in advanced/recurrent non‐small cell lung carcinoma

المؤلفون: Takashi Kasai, Ryo Arai, Masahiko Okada, Ayako Takigami, Ichiro Nakachi, Takayuki Kishikawa, Masafumi Sata, Sayo Soda

المصدر: Thoracic Cancer, Vol 11, Iss 4, Pp 935-942 (2020)
Thoracic Cancer

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Lung Neoplasms, Tyrosine-kinase inhibitor, T790M, tyrosine kinase inhibitor, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Osimertinib, Aged, 80 and over, Aniline Compounds, General Medicine, Middle Aged, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, ErbB Receptors, Survival Rate, osimertinib, 030220 oncology & carcinogenesis, Female, Original Article, Adult, non‐small cell lung cancer, Pulmonary and Respiratory Medicine, medicine.medical_specialty, medicine.drug_class, Adenocarcinoma of Lung, Neutropenia, lcsh:RC254-282, 03 medical and health sciences, Internal medicine, medicine, Humans, Adverse effect, Protein Kinase Inhibitors, Aged, Retrospective Studies, Pneumonitis, Acrylamides, Proportional hazards model, business.industry, Original Articles, medicine.disease, respiratory tract diseases, Epidermal growth factor receptor T790M mutation, 030104 developmental biology, Carcinoma, Large Cell, Recurrent Non-Small Cell Lung Carcinoma, Neoplasm Recurrence, Local, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd21b221710ea3d5f464c5dcc42b683dTest
https://doi.org/10.1111/1759-7714.13378Test

9

Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma

المصدر: Future Oncology. 15:1911-1920

مصطلحات موضوعية: Male, 0301 basic medicine, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Programmed Cell Death 1 Receptor, Postmarketing surveillance, Severity of Illness Index, Ground-glass opacity, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Humans, Medicine, Lung cancer, Melanoma, Aged, Pneumonitis, Aged, 80 and over, business.industry, Interstitial lung disease, Pneumonia, General Medicine, Middle Aged, medicine.disease, Radiography, Nivolumab, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Radiological weapon, Female, Radiology, medicine.symptom, Tomography, X-Ray Computed, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::925019da69eb257dba887360e460d06eTest
https://doi.org/10.2217/fon-2019-0102Test

10

Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody

المؤلفون: Kazushige Wakuda, Satoshi Ikeda, Masafumi Sata, Ryota Ushio, Kentaro Ito, Takashi Sato, Shigeru Tanzawa, Naoki Furuya, Makoto Nishino

المصدر: Thoracic Cancer
Thoracic Cancer, Vol 12, Iss 5, Pp 613-618 (2021)

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Adult, Male, atezolizumab, non‐small cell lung cancer, medicine.medical_specialty, Lung Neoplasms, Pembrolizumab, Antibodies, Monoclonal, Humanized, lcsh:RC254-282, Cohort Studies, 03 medical and health sciences, anti‐PD‐L1, 0302 clinical medicine, Atezolizumab, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Humans, Lung cancer, Immune Checkpoint Inhibitors, Aged, Retrospective Studies, Aged, 80 and over, Performance status, business.industry, Anti pd 1, General Medicine, Original Articles, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Confidence interval, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Retreatment, Female, Original Article, Nivolumab, business, Cohort study

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12194075aa42c60389387090977b3ce3Test
https://pubmed.ncbi.nlm.nih.gov/33448648Test

تنقيح النتائج